This review discusses current thoughts on the pathogenesis of vasculitis. Secondary vasculitides, frequently associated with infections or systemic autoimmune diseases, are, in most cases, characterized by immune deposits in the vessel wall, which probably underlies the development of lesions. In the primary vasculitides, immune deposits are generally absent. A group of primary vasculitides is, however, strongly associated with anti-neutrophil cytoplasmic autoantibodies (ANCA). Various in vitro and in vivo experimental data suggest that those ANCA are involved in the pathogenesis of lesions in the associated disorders.
Introduction
The systemic vasculitides comprise a diverse group of disorders characterized by in¯ammation of the blood vessel wall. The localization and size of the in¯amed vessels and the nature of the in¯ammatory process, as well as its systemic effects, determine the clinical presentation of the disorder.
Vasculitis may, incidentally, result from direct invasion of the blood vessel wall by micro-organisms or from microbial embolization. 1 Many cases of vasculitis are secondary to other diseases. These secondary vasculitides are frequently characterized by immune complex deposition, as will be discussed later on. In the remainder of cases in which vasculitis is histopathologically demonstrable, no underlying disorder or direct infection of the vessel wall can be detected. Those primary or idiopathic vasculitides constitute a heterogeneous group of disorders that are classi®ed based on the size of the vessels involved, the histopathological ®ndings and the clinical symptoms (Table 1 ). 2 ± 4 The pathogenesis of the primary vasculitides is far from understood, but recent developments have shed some light on the pathophysiological processes underlying those disorders.
In this review the pathogenetic pathways in the secondary vasculitides will be brie¯y discussed. The main focus will, however, be on recent studies on the pathogenesis of the primary vasculitides.
Secondary vasculitides
As stated before, many cases of secondary vasculitis demonstrate immune deposits within the vessel wall by direct immuno¯uorescence. A classical example is the occurrence of leucocytoclastic vasculitis, clinically apparent as purpura, in patients with cryoglobulinemia as part of Sjùgren's syndrome. Cryoglobulins composed of monoclonal rheumatoid factor and polyclonal immunoglobulin G are deposited in the vessel wall and activate the complement cascade along the classical pathway. Neutrophils are attracted and activated, and invade the vessel wall resulting in leucocytoclastic vasculitis. Activation of the complement cascade with consumption of complement components is demonstrable by decreased levels of complement C3 and C4 and increased levels of C3d, a breakdown product of C3 after activation. In addition, circulating immune complexes can be detected in serum.
Immune complex-mediated vasculitis has been suggested to occur in association with systemic autoimmune diseases and infections. 5 In the systemic autoimmune diseases, particularly systemic lupus erythematosus (SLE), nuclear antigens and their corresponding antibodies have been thought to be pathogenetically involved. Recent ®ndings do, however, support an (additional) mechanism in which the antigen is ®rst planted in the vessel wall. Binding of nucleohistones to the (glomerular) basement membrane in lupus nephritis, due to charge interaction, is followed by binding of antibodies. 6 This in situ immune complex formation may be operative in many cases of immune complex-mediated vasculitis.
Besides systemic autoimmune diseases, infections are associated with vasculitis. Bacterial and viral infections may induce the formation of immune complexes consisting of microbial antigens and their corresponding antibodies which, either by deposition from the circulation or by in situ formation, results in vasculitides. The association of cryoglobulinemia with, particularly, hepatitis C virus (HCV) 7, 8 is remarkable in this respect. Different mechanisms may, however, be operative. First, microbes may directly invade the vessel wall followed by an infectious in¯ammatory process. 1 Secondly, certain viruses, such as cytomegalovirus, can penetrate endothelial cells and activate those cells leading, along pathways that still have to be explored, to vasculitis. 8 Thirdly, bacterial antigens from Staphylococci, such as Staphylococcal neutral phosphatase, can attach to basement membranes and bind IgG non-speci®cally, 9 also resulting in immune complex formation. Thus, microbial agents are de®nitely involved in the etiopathogenesis of vasculitis. The precise pathophysiology of the associated secondary vasculitides is still under study. Also, in other forms of secondary vasculitis, for example, drug-related, the exact pathophysiological mechanisms have not been fully elucidated.
Primary vasculitides
In classical polyarteritis nodosa (PAN) viral infections seem to be involved in some 20% of cases. 8 Hepatitis B virus (HBV) and HCV, as well as HIV and, possibly, parvovirus, have been thought to be causally related to the development of PAN in these cases. The pathophysiological mechanisms are only partly understood, as discussed in the previous section. As mentioned before, HBV-, HCV-, and HIV-infection are in many more cases associated with mixed cryoglobulinemic vasculitis. 7, 8 How those viruses induce cryoglobulins is still open for study.
In the majority of cases with primary vasculitis, exogenous factors are not directly demonstrable. There is increasing evidence that autoimmune responses are operative in those disorders. Although the possible pathogenic role of anti-endothelial cell antibodies and the anti-phospholipid antibodies in systemic vasculitis (reviewed in Ref. 10) should be mentioned, the focus has been on anti-neutrophil cytoplasmic antibodies in recent years.
Anti-neutrophil cytoplasmic antibodies (ANCA) and the pathophysiology of systemic vasculitis
As shown in Table 1 , Wegener's granulomatosis (WG), microscopic polyangiitis (MPA), Churg Table 2 Pathogenic effects of anti-neutrophil cytoplasmic antibodies (ANCA) as derived from in vitro studies 1. Activation of neutrophils primed with low dose TNFa resulting in the production of reactive oxygen intermediates (ROI) and the release of lysosomal enzymes. 13 This process only occurs when neutrophils are allowed to adhere to a surface; this adherence particularly involves the b 2 -integrins. 14 Priming (and apoptosis) results in expression of the target antigens of ANCA on the cell surface making them accessible for ANCA. 15Y16 Neutrophil activation by ANCA is also dependent, probably, on the interaction of the Fc-part of ANCA with, particularly, the FcgRIIa-receptor on neutrophils. 17 ANCA-induced ROI production and degranulation is enhanced in the presence of extracellular arachidonic acid. 18 2. Activation of the 5-lipoxygenase pathway in neutrophils inducing the production of large amounts of leukotriene B4, a potent chemo-attractant for neutrophils. 18 3. Induction of cytokine production such as IL-1b by neutrophils. 19 4. Induction of the production of ROI 20 and monocyte chemo-attractant protein-1, 21 by monocytes. 5. Lysis of endothelial cells previously incubated with myeloperoxidase (MPO) or proteinase 3 (Pr3). 22, 23 Upregulation of adhesion molecules on (primed) endothelial cells. 24 Lysis of (primed) endothelial cells in the presence of neutrophils. 25 
6.
Interference with the inactivation of Pr3 by a 1 -antitrypsin 26 which may result in persistently active Pr3. 
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Strauss Syndrome (CSS) and idiopathic necrotizing crescentic glomerulonephritis (NCGN) are closely associated with autoantibodies to either proteinase 3 (Pr3) or myeloperoxidase (MPO). 11 Changes in titers of those autoantibodies seem to re¯ect changes in disease activity. 12 Those ®ndings suggest that the autoantibodies are involved in the pathophysiology of the associated disorders. Experimental evidence for the pathogenic potential of ANCA has been derived mainly from in vitro studies. Those studies are summarized in Table 2 . One may conclude from those studies, that ANCA are able to aggravate a subclinical in¯ammatory process by activating, along several lines, neutrophils and monocytes. In addition, endothelial cells are potentially a target of ANCA, either indirectly via endothelial binding of Pr3aMPO released from neutrophils, to which the antibodies can bind, or directly by reacting with Pr3 expressed on the surface of endothelial cells as demonstrated by Mayet et al, 27 but disputed by others. 28 Although all of the aforementioned data suggest that ANCA are pathogenic, more direct proof should come from in vivo studies on experimental animals. Until now, a fully satisfactory animal model for ANCA-associated vasculitis has not been developed. Nevertheless, several in vivo models are presently available that support a pathogenic role for ANCA, 29 summarized in Table 3 . In certain models, 30 ± 34 vasculitis andaor crescentic glomerulonephritis develops spontaneously in conjunction with autoantibodies to MPO. The autoantibody response to MPO is, however, part of a more polyclonal autoantibody response which does not allow the analysis of the speci®c contribution of anti-MPO to the development of vasculitis. The anti-antiidiotypic model 38 for anti-Pr3 is interesting but awaits con®rmation as well as further analysis of the lesions. It is important to mention that induction of ANCA (anti-MPO) alone does not result in lesions. 35 ± 37 When, however, products of activated neutrophils are present in the circulation, pauci-immune crescentic glomerulonephritis 35 and systemic vasculitis 37 can develop.
All of the aforementioned in vitro and in vivo experimental data lead to the conclusion that ANCA in combination with exogenous factor(s) that induce pre-activation (priming) of neutrophils, may result in systemic vasculitis and glomerulonephritis. The exogenous factors have not yet been de®ned, but the observations that carriage of Staphylococcus aureus is an important risk factor for relapses in WG 39 and that maintenance treatment with trimethoprima sulfamethoxazole prevents relapses 40 suggest that microbial factors are also involved in the primary vasculitides. Balb-c mouse Immunization with human anti-Pr3
Mouse antibodies to human Pr3
Sterile micro-abscesses in lungs
Anti-anti-idiotypic responses MPO myeloperoxidase; Pr3 proteinase 3.
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T-lymphocytes in the systemic vasculitides
Whereas many experimental and clinical data are available on the role of autoantibodies in systemic vasculitis, the role of T-cells has been explored to a limited extent only. In the ANCA-associated vasculitides T-cell responses of peripheral blood mononuclear cells to Pr3 but hardly to MPO have been documented in patients but also, albeit to a lesser extent, in healthy controls. 41 The functional characteristics of those cells, the epitopes involved, and the analysis of tissue in®ltrating lymphocytes, are still open to study. More interestingly, skewing of the Tcell repertoire due to preferential use of certain Vb genes have been noted in a number of vasculitides, notably in Kawasaki disease, 42 microscopic polyangiitis, 43 and, very recently, in WG. 44 These data can be consistent with antigen or superantigen, particularly staphylococcal superantigen, stimulation. It should, however, be kept in mind that shaping of the peripheral blood T-cell repertoire, also occurs with increasing age. 45 Certainly, more work should be done on T-cells in systemic vasculitis. In this respect, the studies of Weyand and Goronzy 46 on T-cell macrophage interactions in the vessel wall of giant cell arteritis are promising.
Conclusion
The etiopathogenesis of the primary systemic vasculitides has not yet been clari®ed in detail. The detection of anti-neutrophil cytoplasmic antibodies in a number of those diseases has, however, given a huge impulse to the unraveling of pathogenetic pathways operative in the vasculitides. In addition, further analysis of the speci®c immune responses underlying the idiopathic vasculitides may bene®t from recent developments in molecular immunology.
